Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2020 - 2025)

Tarsus Pharmaceuticals has reported Cash & Current Investments over the past 6 years, most recently at $417.3 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $417.3 million for Q4 2025, up 340.07% from a year ago — trailing twelve months through Dec 2025 was $417.3 million (up 340.07% YoY), and the annual figure for FY2025 was $417.3 million, up 340.07%.
  • Cash & Current Investments for Q4 2025 was $417.3 million at Tarsus Pharmaceuticals, up from $401.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for TARS hit a ceiling of $417.3 million in Q4 2025 and a floor of $94.8 million in Q4 2024.
  • Median Cash & Current Investments over the past 5 years was $227.0 million (2022), compared with a mean of $252.4 million.
  • Biggest five-year swings in Cash & Current Investments: tumbled 58.31% in 2024 and later soared 340.07% in 2025.
  • Tarsus Pharmaceuticals' Cash & Current Investments stood at $171.8 million in 2021, then increased by 26.31% to $217.0 million in 2022, then increased by 4.8% to $227.4 million in 2023, then tumbled by 58.31% to $94.8 million in 2024, then surged by 340.07% to $417.3 million in 2025.
  • The last three reported values for Cash & Current Investments were $417.3 million (Q4 2025), $401.8 million (Q3 2025), and $381.1 million (Q2 2025) per Business Quant data.